Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005)

Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005)

Gastrointestinal Stromal Tumor

Unknown

3

Start Date 01/24/2001

Age of Trial (yrs) 23.8

First-line

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

CDR0000596490, EORTC-62005, AGITG-AGO102-GIST, ISG-62005, SSG-15

EORTC, ISG, AGTG SSG

Randomized

Oral

This is the EORTC phase 3 European, Asian and Australian trial for GIST. This trial recruited 946 patients. It started in early 2001 and finished recruitment by 2003. The trial is ongoing but no longer recruiting patients.
The results of this trial (EORTC 62005), the similar US/Canadian phase 3 trial (S0033) and the phase 2 B2222 trial, form the basis of much of what is known about Gleevec for metastatic GIST today. Links to the "meta-analysis" refer to the combined data from this trial and the S0033 phase 3 trial.

Study Chair: Jacob Verweij, MD, PhD Daniel Den Hoed Cancer Center at Erasmus Medical Center
Study Chair: Paolo G. Casali, MD Fondazione Istituto Nazionale dei Tumori
Study Chair: John R. Zalcberg, MB, BS, PhD, FRACP Peter MacCallum Cancer Centre, Australia
Study Chair: Kirsten Sundby Hall, MD Lund University Hospital